Five‐year follow‐up of patients who underwent everolimus‐eluting bioresorbable scaffold implantation

  • Wiebe, Jens
  • Hofmann, Felix J.
  • Dörr, Oliver
  • Bauer, Timm
  • Boeder, Niklas
  • Liebetrau, Christoph
  • Blachutzik, Florian
  • Möllmann, Helge
  • Elsässer, Albrecht
  • Achenbach, Stephan
  • Hamm, Christian W.
  • Nef, Holger M.
Publication date
March 2020
Publisher
Wiley

Abstract

Objectives The aim of this study was to evaluate very long‐term results after unrestricted everolimus‐eluting bioresorbable scaffolds (BRS) implantation. Background Previous randomized studies mainly included selected patients differing from those seen during daily routine and long‐term data from all‐comers registries are sparse. Methods Consecutive patients undergoing BRS implantation were included in this observational, single center study. Clinical follow‐up was conducted up to 5 years. Endpoint of interest was the composite of target lesion failure (TLF), including target‐vessel myocardial infarction and target lesion revascularization and cardiac death. Furthermore, ARC‐defined scaffold thrombosis (ScT) were assessed. ...

Extracted data

We use cookies to provide a better user experience.